Published in Blood on June 03, 2008
Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature (2011) 6.39
Tumour heterogeneity and cancer cell plasticity. Nature (2013) 5.47
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Cancer stem cells: an evolving concept. Nat Rev Cancer (2012) 4.57
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA (2010) 3.25
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood (2012) 2.65
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell (2014) 2.15
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia. Cancer Cell (2013) 1.89
Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther (2008) 1.83
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
The evolving concept of cancer and metastasis stem cells. J Cell Biol (2012) 1.76
Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci U S A (2011) 1.71
Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. Cell (2015) 1.67
A robust xenotransplantation model for acute myeloid leukemia. Leukemia (2009) 1.67
Cancer stem cells: controversial or just misunderstood? Cell Stem Cell (2009) 1.54
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget (2012) 1.50
Identification and targeting of cancer stem cells. Bioessays (2009) 1.44
Understanding the cancer stem cell. Br J Cancer (2010) 1.42
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia (2011) 1.25
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res (2011) 1.23
Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Mol Med (2012) 1.22
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Cancer stem cells: controversies in multiple myeloma. J Mol Med (Berl) (2009) 1.15
High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias. Leukemia (2010) 1.13
Human cancer growth and therapy in immunodeficient mouse models. Cold Spring Harb Protoc (2014) 1.12
AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood (2013) 1.10
p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia (2011) 1.09
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Adv Hematol (2012) 1.09
Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Cell Stem Cell (2015) 1.09
High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica (2011) 1.07
Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells. PLoS One (2013) 1.01
Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation. Leukemia (2011) 0.98
Humanized hemato-lymphoid system mice. Haematologica (2016) 0.98
p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies. Semin Oncol (2012) 0.97
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Therapy targets in glioblastoma and cancer stem cells: lessons from haematopoietic neoplasms. J Cell Mol Med (2013) 0.95
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A (2015) 0.95
Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia (2011) 0.94
Role of heme oxygenase-1 in postnatal differentiation of stem cells: a possible cross-talk with microRNAs. Antioxid Redox Signal (2014) 0.94
Concise review: Cancer stem cells and minimal residual disease. Stem Cells (2012) 0.94
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One (2014) 0.94
In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS One (2013) 0.93
Regulating the leukaemia stem cell. Best Pract Res Clin Haematol (2009) 0.93
Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol (2009) 0.92
A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Mol Cell Proteomics (2012) 0.92
Mouse models of myelodysplastic syndromes. Hematol Oncol Clin North Am (2010) 0.90
Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol (2013) 0.90
Cancer stem cells: a stride towards cancer cure? J Cell Physiol (2010) 0.90
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia (2014) 0.90
Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages. Stem Cell Reports (2014) 0.89
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J (2014) 0.88
Cancer stem cell targeted therapy: progress amid controversies. Oncotarget (2015) 0.88
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS One (2015) 0.87
Diverging fates of cells of origin in acute and chronic leukaemia. EMBO Mol Med (2012) 0.86
SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment. Nat Commun (2015) 0.86
Acute myelogenous leukemia stem cells: from Bench to Bedside. Cancer Lett (2012) 0.86
Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells. Blood (2014) 0.86
Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells. PLoS One (2013) 0.85
Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia. World J Stem Cells (2014) 0.85
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res (2010) 0.85
Runx1 deficiency permits granulocyte lineage commitment but impairs subsequent maturation. Oncogenesis (2013) 0.84
The mammary cellular hierarchy and breast cancer. Cell Mol Life Sci (2014) 0.84
Targeting myelogenous leukemia stem cells: role of the circulation. Front Oncol (2012) 0.84
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells. Cancer Res (2013) 0.84
Regeneration-associated WNT signaling is activated in long-term reconstituting AC133bright acute myeloid leukemia cells. Neoplasia (2012) 0.83
The vent-like homeobox gene VENTX promotes human myeloid differentiation and is highly expressed in acute myeloid leukemia. Proc Natl Acad Sci U S A (2010) 0.83
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl Med (2014) 0.82
An evolutionary explanation for the presence of cancer nonstem cells in neoplasms. Evol Appl (2012) 0.82
A niche-like culture system allowing the maintenance of primary human acute myeloid leukemia-initiating cells: a new tool to decipher their chemoresistance and self-renewal mechanisms. Stem Cells Transl Med (2014) 0.82
The novel function of CD82 and its impact on BCL2L12 via AKT/STAT5 signal pathway in acute myelogenous leukemia cells. Leukemia (2015) 0.82
Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia. Leukemia (2014) 0.81
Prostate cancer stem cell biology. Minerva Urol Nefrol (2012) 0.81
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia (2016) 0.80
[Tumor stem cell research - basis and challenge for diagnosis and therapy]. Wien Klin Wochenschr (2010) 0.80
Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood (2016) 0.79
Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology (2013) 0.79
Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Cancer Cell (2011) 0.78
Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connect Tissue Res (2015) 0.78
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality. Oncotarget (2016) 0.78
Cancer stem cells: relevance to SCT. Bone Marrow Transplant (2009) 0.77
Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biology. Blood (2014) 0.77
TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia. Oncotarget (2015) 0.77
Understanding melanoma stem cells. Melanoma Manag (2015) 0.77
Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion. Oncotarget (2016) 0.77
Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep (2015) 0.77
High-Dimensional Analysis of Acute Myeloid Leukemia Reveals Phenotypic Changes in Persistent Cells during Induction Therapy. PLoS One (2016) 0.76
Systematic analysis of hematopoietic gene expression profiles for prognostic prediction in acute myeloid leukemia. Sci Rep (2015) 0.76
Fluorouracil selectively enriches stem-like leukemic cells in a leukemic cell line. Int J Biol Sci (2010) 0.76
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells (2016) 0.76
Revised response criteria for malignant lymphoma. J Clin Oncol (2007) 22.19
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med (2004) 12.20
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol (2014) 6.61
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias. Cancer Res (2005) 3.83
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol (2009) 3.19
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell (2011) 3.12
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells (2005) 3.00
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med (2004) 2.97
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood (2010) 2.72
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood (2008) 2.72
Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res (2005) 2.66
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood (2012) 2.37
Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol (2007) 2.36
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood (2011) 2.32
AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood (2005) 2.28
CD64 distinguishes macrophages from dendritic cells in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages during colitis. Eur J Immunol (2012) 2.27
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol (2011) 2.26
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest (2005) 2.15
Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol (2011) 2.14
An antagonistic pair of FT homologs mediates the control of flowering time in sugar beet. Science (2010) 2.07
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood (2004) 2.01
Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol (2008) 1.99
Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol (2002) 1.98
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
FLT3 mutations in childhood acute lymphoblastic leukemia. Blood (2003) 1.91
Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib. Blood (2008) 1.90
Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis (2006) 1.78
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study. J Clin Oncol (2012) 1.77
Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood (2012) 1.74
In vivo contribution of murine mesenchymal stem cells into multiple cell-types under minimal damage conditions. J Cell Sci (2004) 1.73
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol (2006) 1.68
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res (2009) 1.65
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood (2008) 1.65
CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell (2013) 1.65
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol (2013) 1.63
Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol (2007) 1.62
The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. Blood (2013) 1.62
Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood (2006) 1.62
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A (2009) 1.61
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood (2013) 1.61
Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells (2007) 1.59
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol (2013) 1.58
SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma. Blood (2011) 1.57
DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood (2012) 1.56
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood (2008) 1.56
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol (2012) 1.55
The vitamin D receptor is a Wnt effector that controls hair follicle differentiation and specifies tumor type in adult epidermis. PLoS One (2008) 1.53
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood (2007) 1.53
Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.50
Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol (2007) 1.50
The role of B7 family molecules in hematologic malignancy. Blood (2012) 1.47
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int (2005) 1.46
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol (2006) 1.45
Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol (2007) 1.45
Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease. Proc Natl Acad Sci U S A (2008) 1.44
Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer (2003) 1.43
Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res (2008) 1.42
Trends in Mohs surgery from 1995 to 2010: an analysis of nationally representative data. Dermatol Surg (2015) 1.42
Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood (2012) 1.41